Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82667 | 1.00 | DPP4 (0.42) | DPP4METAP1ALOX5METAP2ANPEP | |
| SCHEMBL2585787 | 1.00 | DPP4 (0.42) | DPP4METAP1ALOX5METAP2ANPEP | |
| Hydrochloric Acid SCHEMBL8815090 | 0.98 | DPP4 (0.41) | DPP4METAP1ALOX5METAP2ANPEP | |
| Hydrochloric Acid SCHEMBL629206 | 0.98 | DPP4 (0.41) | DPP4METAP1ALOX5METAP2ANPEP | |
| Hydrochloric Acid SCHEMBL629207 | 0.98 | DPP4 (0.41) | DPP4METAP1ALOX5METAP2ANPEP | |
| SCHEMBL24324140 | 0.98 | DPP4 (0.41) | DPP4METAP1ALOX5METAP2ANPEP | |
| SCHEMBL24323716 | 0.98 | DPP4 (0.41) | DPP4METAP1ALOX5METAP2ANPEP | |
| SCHEMBL24324582 | 0.93 | — | — | |
| SCHEMBL14889552 | 0.93 | — | — | |
| SCHEMBL3322576 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20010044012-A1 | Transparent substrate between a hydrophilic ink receiving layer and a colored hydrophobic luminescent layer; creating photographic quality prints | XEROX CORPORATION | 2001-11-22 | — | — | US | claimed |
| US-6319591-B1 | Ink jet recording substrates | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | claimed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | claimed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | claimed |
| US-6066200-A | COMPRISING A SOLID UREA COMPOUND, AN ALCOHOL, A LIGHTFASTNESS COMPONENT, A LIGHTFAST ANTIOXIDANT, AND A COLORANT | XEROX CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| US-11944941-B2 | Chemoselective nanoporous membranes | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023043836-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| CN-1163145-A | Inhibiting agent for vascular formation | SENJI SEIYAKU K K (JP) | 1997-10-29 | — | — | CN | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | DPP4 2996/4885METAP1 1442/4885ALOX5 2361/4885 |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | DPP4 414/4885METAP1 1271/4885ALOX5 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.